%0
Generic
%T
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.
%A Wierda, William G.
%A Jacobs, Ryan
%A Barr, Paul M.
%A Allan, John N.
%A Siddiqi, Tanya
%A Tedeschi, Alessandra
%A Kipps, Thomas J.
%A O'Brien, Susan Mary
%A Badoux, Xavier C.
%A Visentin, Andrea
%A Lasica, Masa
%A Carney, Dennis
%A Elinder Camburn, Anna
%A De La Serna Torroba, Javier
%A Szafer-Glusman, Edith
%A Zhou, Cathy
%A Szoke, Anita
%A Dean, James P.
%A Ghia, Paolo
%A Tam, Constantine S.
%I American Society of Clinical Oncology (ASCO)
%@ 0732-183X
%@ 1527-7755
%D 2024
%C American Society of Clinical Oncology (ASCO)